Study of Tumour Response to Tirapazamine During Treatment of Cervical CancerS9717 Tirapazamine Plus Cisplatin in Treating Patients With Metastatic, Recurrent, or Refractory Cervical CancerCombination of TATE and PD-1 Inhibitor in Liver CancerDose-defining Study of Tirapazamine Combined With Embolization in Liver CancerCisplatin and Radiation Therapy With or Without Tirapazamine in Treating Patients With Cervical CancerTRACE: Tirapazamine-Radiation And Cisplatin EvaluationConcomitant Radiation and Cisplatin With and Without Tirapazamine in Treatment of Advanced Head and Neck CancerTirapazamine Plus Cyclophosphamide in Treating Children With Refractory Solid TumorsRadiation Therapy and Combination Chemotherapy in Treating Patients With Stage III or Stage IV Head and Neck CancerS0004: Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Limited-stage Small Cell Lung CancerCisplatin Plus Vinorelbine With or Without Tirapazamine in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung CancerTirapazamine Combined With Chemo and RT in Limited-Stage Small Cell Lung CancerTirapazamine Plus Cisplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Primary Peritoneal CancerCombination Chemotherapy With or Without Tirapazamine in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung CancerChemotherapy, Tirapazamine, and Radiation Therapy in Treating Patients With Non-Small Cell Lung CancerTirapazamine, Carboplatin, and Paclitaxel in Treating Patients With Advanced Malignant Solid TumorsComparison of Chemotherapy Regimens in Treating Children With Relapsed or Progressive RhabdomyosarcomaTATE Versus TACE in Intermediate Stage HCCTirapazamine, Cisplatin, and Radiation Therapy in Treating Patients With Stage IB, Stage II, Stage III, or Stage IVA Cervical Cancer
P4844
Phase III randomized trial of weekly cisplatin and irradiation versus cisplatin and tirapazamine and irradiation in stages IB2, IIA, IIB, IIIB, and IVA cervical carcinoma limited to the pelvis: a Gynecologic Oncology Group study.Is there a role for tirapazamine in the treatment of cervical cancer?Tirapazamine sensitizes hepatocellular carcinoma cells to topoisomerase I inhibitors via cooperative modulation of hypoxia-inducible factor-1α.Enhanced antitumor efficacy of cisplatin by tirapazamine-transferrin conjugate.Tirapazamine-doxorubicin interaction referring to heart oxidative stress and Ca²⁺ balance protein levels.The anticancer drug tirapazamine has antimicrobial activity against Escherichia coli, Staphylococcus aureus and Clostridium difficile.Correlation of p16 status, hypoxic imaging using [18F]-misonidazole positron emission tomography and outcome in patients with loco-regionally advanced head and neck cancer.SR-4233 (Tirapazamine) acts as an uncoupler of oxidative phosphorylation in human MCF-7 breast carcinoma cellsEffects of tirapazamine on experimental colorectal liver metastases after radiofrequency ablationUsefulness of combined treatment with continuous administration of tirapazamine and mild temperature hyperthermia in γ-ray irradiation in terms of local tumour response and lung metastatic potential
P921
Q61917807-F7AB784B-E9AE-4136-8C06-2F072FA801C3Q62110579-4F2FBE11-E9CB-4D0A-99A4-B58F735E95C0Q64836893-5AEF6C31-C498-4428-BAA1-A9C251E9074BQ65353706-E5F509DB-29AD-4616-BE99-A7BECFC7260FQ65541571-857F20EB-9501-4D40-85E0-C5C89D7E136CQ66026851-4B0321B1-C6D2-4313-95FF-92202106AF6EQ66031893-16A21FE3-E580-478E-8CF8-19D3DD67FCE2Q66032564-5D6F11A8-33D8-4DA2-8B0A-DA29E708613BQ66034154-93601AAD-66B2-4175-8198-76480AC8E1E0Q66034195-93662100-B23C-49AA-A991-18E49E16BCC7Q66035100-138EDBCC-9A59-4B91-A296-5A18270BBE38Q66035220-36FB0F8D-8D7B-4DE8-B782-7E959974B0F6Q66035384-39C963E3-6855-4187-9729-FFB19104438DQ66036156-CDA5EDAD-F40C-49A9-A18C-EB52B4E424D9Q66036218-53129882-2295-4A35-A502-ADD5ABFD87B6Q66036322-364F7494-DC3F-4F9E-8FCB-BD2D6B7A0505Q66036650-CD905A71-7BF5-4C87-9152-6AEB64CF7722Q66045086-2E705CBB-C8EC-4EF6-9B02-7524FDFB98AEQ66059181-8FF62D3B-0C2F-4212-8BC7-E17EB15B609A
P4844
Q30408170-4A72EF37-6DFB-4484-AD34-F2F8FBAF4061Q38049169-F4608624-118E-4FBF-999A-63F03F38C2B3Q39041058-6C6C7BBF-19F9-4C20-9CD4-62D3D1267ADFQ39359242-F66ED942-D004-416A-863E-36FA56C3E590Q41991319-B18F68F5-5037-42E3-B245-5E6263E0290FQ47929929-E97B508B-9D71-47C1-9AA4-F5C6643923D3Q51111745-3F94E098-8776-4DDE-9DB7-410EC31D70FEQ72789626-8C5C254C-CF8D-4687-86E4-6205C82B6F92Q83440298-227591A5-99C5-4C04-A65B-EF503D6EFEC3Q84931724-3D439A20-E8E6-4D29-ADCF-DFDD41522800
P921
description
chemesch Verbindung
@lb
chemical compound
@en
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de
chemische Verbindung
@de-ch
chemische verbinding
@nl
name
Tirapazamin
@sh
Tirapazamin
@sr
Tirapazamine
@en
Tirapazamine
@fr
type
label
Tirapazamin
@sh
Tirapazamin
@sr
Tirapazamine
@en
Tirapazamine
@fr
altLabel
27314-97-2
@fr
C7H6N4O2
@fr
SR-4233
@fr
prefLabel
Tirapazamin
@sh
Tirapazamin
@sr
Tirapazamine
@en
Tirapazamine
@fr
P486
P592
P6366
P662
P665
P683
P1579
P231
27314-97-2
P232
P233
C1=CC=C2C(=C1)[N+](=C(N=[N+]2[O-])N)[O-]
c1ccc2c(c1)[n+](c(n[n+]2[O-])N)[O-]
P234
1S/C7H6N4O2/c8-7-9-11(13)6-4-2-1-3-5(6)10(7)12/h1-4H,(H2,8,9)
P235
ORYDPOVDJJZGHQ-UHFFFAOYSA-N
P2566
100.164.453
P274
P2840
P486
P592
CHEMBL50882
P6366
2776313096
P652
1UD32YR59G